TY - JOUR
T1 - Fundament and prerequisites for the application of an antifungal TDM service
AU - Brüggemann, Roger J.M.
AU - Aarnoutse, Rob E.
N1 - Publisher Copyright:
© The Author(s) 2015.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Therapeutic drug monitoring (TDM) involves the measurement of plasma or serum drug concentration to adapt dosages to achieve predefined target concentrations that are associated with optimal clinical response while minimizing the chance of encountering toxicity. Many papers in the field of antifungal drugs have focused on the evidence that supports the use of TDMthereby emphasizing the breakpoints or target concentrations in general literature. This review focuses on the process of TDM to inform health care workers on the fundaments and prerequisites that safeguard the good application of TDM. Knowledge on the complete process of TDMincluding pharmacokinetics (and relevant covariates), pharmacodynamic aspects, trials that are necessary to provide uswith evidence, translation of knowledge to other populations and pathogens, and implications for the pre-analytical, analytical, and postanalytical phases (the process of TDM) are discussed in relevant detail. For each individual step, recommendations are made for the readers. We believe this will be a valuable resource and to be of added value to the many papers that focus on relations between exposure and efficacy or toxicity. It will help to achieve greater benefit of TDM.
AB - Therapeutic drug monitoring (TDM) involves the measurement of plasma or serum drug concentration to adapt dosages to achieve predefined target concentrations that are associated with optimal clinical response while minimizing the chance of encountering toxicity. Many papers in the field of antifungal drugs have focused on the evidence that supports the use of TDMthereby emphasizing the breakpoints or target concentrations in general literature. This review focuses on the process of TDM to inform health care workers on the fundaments and prerequisites that safeguard the good application of TDM. Knowledge on the complete process of TDMincluding pharmacokinetics (and relevant covariates), pharmacodynamic aspects, trials that are necessary to provide uswith evidence, translation of knowledge to other populations and pathogens, and implications for the pre-analytical, analytical, and postanalytical phases (the process of TDM) are discussed in relevant detail. For each individual step, recommendations are made for the readers. We believe this will be a valuable resource and to be of added value to the many papers that focus on relations between exposure and efficacy or toxicity. It will help to achieve greater benefit of TDM.
KW - Antifungalagents
KW - Isavuconazole
KW - Pharmacokinetics
KW - Posaconazole
KW - Therapeutic drugmonitoring
KW - Triazoles
KW - Voriconazole
UR - https://www.scopus.com/pages/publications/84943353257
U2 - 10.1007/s12281-015-0224-3
DO - 10.1007/s12281-015-0224-3
M3 - Article
AN - SCOPUS:84943353257
SN - 1936-3761
VL - 9
SP - 122
EP - 129
JO - Current Fungal Infection Reports
JF - Current Fungal Infection Reports
IS - 2
M1 - A008
ER -